Tucson, AZ – September 18th, 2025 – ZelosDx, welcomes John Grant, PhD to it's Board of Directors.
Dr. Grant first connected with ZelosDx at the 2022 BioTools Innovation Competition and later became a valued advisor and investor. He brings extensive expertise in business development, acquisitions, investment, and leadership across both major corporations and early-stage ventures.
Tucson, AZ – September 11th, 2025 – ZelosDx, a biotechnology company advancing brain health diagnostic tools, announced today the appointment of Dr. Alie J. Buckmire as the company’s new Chief Executive Officer. He succeeds Marie Wesselhoft, co-founder and president, who will continue to serve on the board of directors.
Dr. Buckmire’s appointment marks a significant new phase in ZelosDx’s mission to accelerate breakthrough discoveries in brain disease and signals the beginning of the company’s next chapter: innovation, scale, and market expansion.
“I am excited and honored to lead ZelosDx at such an important inflection point,” said Dr. Buckmire. “ZelosDx is built on an amazing technology. My focus is to drive novel solutions, explore new opportunities for growth, and build success.”
“From the start, our goal was to give researchers and drug developers a clearer window into the brain,” said Marie Wesselhoft, co-founder and president.
“ZelosDx is uniquely positioned to capitalize on this opportunity by unlocking a new dimension in neurological blood testing. With Dr. Buckmire stepping in as CEO, I believe we are ready to turn this vision into reality and accelerate the impact of our technology.”
“Dr. Buckmire brings the vision and leadership to take ZelosDx to its next stage of growth,” said Conrad Plimpton, chairman of the board. “With his expertise in translational science and deep commitment to collaboration, we are well positioned to advance partnerships with research institutions, biopharma, and clinical teams—and to deliver new diagnostic tools that can change the way brain disease is managed.”
Dr. Buckmire earned his PhD in Neuroscience from the University of Arizona and previously held leadership roles at McKesson and Misys Healthcare. He is known for innovative problem-solving, strategic thinking, and a track record of building partnerships.
About ZelosDx
ZelosDx is a biotechnology company advancing brain health diagnostic tools. The company develops novel blood tests that reveal neurological biomarkers to support disease diagnosis, drug discovery, disease monitoring, and therapeutic evaluation. Founded in 2010, ZelosDx’s mission is to accelerate discoveries in brain disease.
Tucson, AZ, October 28, 2022 – ZelosDx, announced today that Dr. John L. Grant, a former 3M Business Development executive and founder of Lemnos Advisory, LLC has joined the newly formed business advisory board of ZelosDx.
Dr. John L. Grant currently is the principal of Lemnos Advisory, LLC, a boutique consultancy which serves clients such as operating companies, transaction advisors, investment banks and venture investors. Dr. Grant is a NACD Certified Director and serves on two startup boards, three non-profit boards, is an advisory board member at two startups and works with BioTools Innovator (Los Angeles) as a mentor. Additionally, he provides strategic support to CXO Advisors (Phoenix), an impact-focused incubator. He also invests in early-stage companies and is on the Investment Committee of Purple Arch Ventures (Chicago) and invests through angel groups such as TCA-LA (Los Angeles), Gopher Angels (Minneapolis) and Chemical Angels Network (SoCal). Previously, he was an executive at 3M and led global strategy and external business development in several 3M divisions within 3M’s Healthcare and Industrial Business Groups. In these roles, he led and participated in 25 acquisitions, divestitures and minority corporate venture investments in advanced materials, filtration, medical devices, biotechnology, industrial adhesives, and enterprise software. His educational background consists of an MBA from the Carlson School of Management at the University of Minnesota and a PhD from Northwestern University.
It is a pleasure to have Dr. Grant join our newly formed business advisory board,” says Marie Wesselhoft, President, and co-founder of ZelosDx. “As we prepare for the commercial launch of our novel WINDOW INTO THE BRAINTM blood testing products, the time is right to be thinking more broadly about the business development options available to us. Dr. Grant’s successful track record in business and fundraising will augment the ZelosDx team.
About ZelosDx, Inc.
ZelosDx is accelerating breakthrough discoveries in brain disease and health with novel blood testing products we call WINDOW INTO THE BRAINTM. The ZelosDx proprietary biomarker technology can be used by pharmaceutical companies as tools for drug discovery and by researchers conducting studies in brain disease. Our blood tests offer a novel approach (single cell analysis vs. serum), a simple, minimally invasive (small amounts of blood), and significantly more cost effective (than existing) assay systems. More successful studies and drug trials produce more effective treatments. ZelosDx is working to build a commercially feasible business, while also responsibly addressing an increasingly important US healthcare need.
The company is in Tucson, Arizona. Please visit www.zelosdx.com for more information about the company and their patented technology.
Last week on October 6, 2021, our ZelosDx data was highlighted in a poster presentation given by our Arizona State University collaborator at the 2021 GRAND CHALLENGES IN PARKINSON'S DISEASE Conference. Vladislav Voziyanov, PhD, Graduate Research Assistant at Arizona State University (ASU), presented the poster titled. “Blood Draws to Assess Biomarkers of Inflammation in Peripheral Blood Monocytes in Response to Chronic Implants for Deep Brain Stimulation.” This data in this poster shows that the novel, ZelosDx blood-based assay can detect trace amounts of Glial Fibrillary Acidic in rodent peripheral blood monocytes offering a non-invasive method of measuring inflammation. This work is a part of a collaboration with the laboratory of Dr. Jitendran Muthuswamy at the ASU School of Biological and Health System's Engineering. https://sols.asu.edu/jitendran-muthuswamy
ABOUT GRAND CHALLENGES CONFERENCE- VAN ANDEL INSTITUTE
Grand Challenges in Parkinson’s Disease is an annual scientific symposium that brings together scientists, clinicians, advocates, and people with Parkinson’s to explore the latest innovative Parkinson’s disease research.
TUCSON, AZ, July 27, 2021 – ZelosDx, Inc. announced today that the company is the recipient of a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation (NSF) for a grant entitled, “ Phagocytic Cells in Peripheral Blood as a Novel Diagnostic Tool for Brain Health”. The company will receive a one-year grant of up to $255,000 to expand the company’s pioneering biomarker research.
ZelosDx plans to demonstrate that phagocytic cells in peripheral blood present a novel tool for a rapid and low-cost diagnostics of brain health, and to provide such a tool to the clinical research community to enable breakthrough discoveries in disease onset and progression, drug development and patient care.
In June, our collaborator from Arizona State University, Dr. Jitendran Muthuswamy, presented a poster highlighting our WINDOW INTO THE BRAIN results at the annual North American Neuromodulation Society (NANS) Conference.
As of August 2020, MsDx has re-branded as ZelosDx